Q1 2016 13F Holders as of 31 Mar 2016
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
56,047,431
-
Number of holders
-
209
-
Total 13F shares, excl. options
-
44,933,850
-
Shares change
-
+342,529
-
Total reported value, excl. options
-
$685,195,121
-
Value change
-
+$7,308,210
-
Put/Call ratio
-
33%
-
Number of buys
-
111
-
Number of sells
-
-105
-
Price
-
$15.25
Significant Holders of SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (SUPN) as of Q1 2016
238 filings reported holding SUPN - SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share as of Q1 2016.
SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (SUPN) has 209 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 44,933,850 shares
of 56,047,431 outstanding shares and own 80% of the company stock.
Largest 10 shareholders include BlackRock Fund Advisors (2,826,989 shares), Ranger Investment Management, L.P. (2,410,586 shares), GLENMEDE TRUST CO NA (1,840,280 shares), VANGUARD GROUP INC (1,778,828 shares), Apex Capital Management (1,483,104 shares), ACADIAN ASSET MANAGEMENT LLC (1,459,407 shares), FMR LLC (1,261,700 shares), Bank of New York Mellon Corp (1,235,769 shares), Invesco Ltd. (1,208,345 shares), and Neumeier Poma Investment Counsel LLC (1,203,930 shares).
This table shows the top 209 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.